Patents by Inventor Makonen Belema

Makonen Belema has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of human immunodeficiency virus replication
    Patent number: 11958834
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: April 16, 2024
    Assignee: VIIV Healthcare UK (No.5) Limited
    Inventors: Makonen Belema, Manoj Patel
  • 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
    Patent number: 11505543
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: November 22, 2022
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Makonen Belema, John A. Bender, David B. Frennesson, Eric P. Gillis, Christiana Iwuagwu, John F. Kadow, B. Narasimhulu Naidu, Kyle E. Parcella, Kevin M. Peese, Ramkumar Rajamani, Mark G. Saulnier, Alan Xiangdong Wang, Manoj Patel, Michael S. Bowsher
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20210214345
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: August 7, 2019
    Publication date: July 15, 2021
    Inventors: Makonen BELEMA, Manoj PATEL
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 10954252
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: March 23, 2021
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Suresh Babu, Makonen Belema, John A. Bender, Christiana Iwuagwu, John F. Kadow, Selvakumar Kumaravel, Pulicharla Nagalakshmi, B. Narasimhulu Naidu, Manoj Patel, Kevin M. Peese, Ramkumar Rajamani, Mark Saulnier, Alan Xiangdong Wang
  • 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20210024503
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: April 11, 2019
    Publication date: January 28, 2021
    Inventors: Makonen BELEMA, John A. BENDER, David B. FRENNESSON, Eric P. GILLIS, Christiana IWUAGWU, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Ramkumar RAJAMANI, Mark G. SAULNIER, Alan Xiangdong WANG, Manoj PATEL, Michael S. BOWSHER
  • Hepatitis C virus inhibitors
    Patent number: 10617675
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: David B. Frennesson, Piyasena Hewawasam, Omar D. Lopez, Van N. Nguyen, Mark G. Saulnier, Yong Tu, Alan Xiangdong Wang, Gan Wang, Ningning Xu, Roshan Yadavrao Nimje, Hasibur Rahaman, Samayamunthula Venkata Satya Arun Kumar Gupta, Nicholas A. Meanwell, Makonen Belema
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20200055839
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: January 2, 2018
    Publication date: February 20, 2020
    Inventors: Makonen BELEMA, Michael S. BOWSHER, Jeffrey A. DESKUS, Kyle J. EASTMAN, Eric P. GILLIS, David B. FRENNESSON, Christiana IWUAGWU, John F. KADOW, B. Narasimhulu NAIDU, Kyle E. PARCELLA, Kevin M. PEESE, Mark G. SAULNIER, Prasanna SIVAPRAKASAM
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 10221129
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 5, 2019
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John A. Bender, Robert G. Gentles, Annapurna Pendri, Alan Xiangdong Wang, Nicholas A. Meanwell, Brett R. Beno, Robert A. Fridell, Makonen Belema, Van N. Nguyen, Zhong Yang, Gan Wang, Selvakumar Kumaravel, Srinivasan Thangathirupathy, Rajesh Onkardas Bora, Shilpa Maheshwarappa Holehatti, Mallikarjuna Rao Mettu, Manoranjan Panda
  • Hepatitis C virus inhibitors
    Patent number: 10047056
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: August 14, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Makonen Belema, Van N. Nguyen
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20180221342
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 9, 2018
    Inventors: David B. Frennesson, Piyasena Hewawasam, Omar D. Lopez, Van N. Nguyen, Mark G. Saulnier, Yong Tu, Alan Xiangdong Wang, Gan Wang, Ningning Xu, Roshan Yadavrao Nimje, Hasibur Rahaman, Samayamunthula Venkata Satya Arun Kumar Gupta, Nicholas A. Meanwell, Makonen Belema
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 10035760
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth:
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: July 31, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180086697
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: April 22, 2016
    Publication date: March 29, 2018
    Inventors: John A. BENDER, Robert G. GENTLES, Annapurna PENDRI, Alan Xiangdong WANG, Nicholas A. MEANWELL, Brett R. BENO, Robert A. FRIDELL, Makonen BELEMA, Van N. NGUYEN, Zhong YANG, Gan WANG, Selvakumar KUMARAVEL, Srinivasan THANGATHIRUPATHY, Rajesh Onkardas BORA, Shilpa Maheshwarappa HOLEHATTI, Mallikarjuna Rao METTU, Manoranjan PANDA
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20180072997
    Abstract: Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Application
    Filed: April 22, 2016
    Publication date: March 15, 2018
    Inventors: John A. BENDER, Omar D. LOPEZ, Van N. NGUYEN, Zhong YANG, Alan Xiangdong WANG, Gan WANG, Nicholas A. MEANWELL, Brett R. BENO, Robert A. FRIDELL, Makonen BELEMA, Srinivasan THANGATHIRUPATHY
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 9855230
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: January 2, 2018
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Makonen Belema, John A. Bender, Brett Beno, Robert G. Gentles, Guo Li, Nicholas A. Meanwell, Annapurna Pendri, Zhong Yang, Shirong Zhu
  • HEPATITIS C VIRUS INHIBITOR
    Publication number: 20170355689
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 14, 2017
    Inventors: RICO LAVOIE, John A. Bender, Zhong Yang, Makonen Belema, Omar D. Lopez, Qi Chen, Gan Wang, Piyasena Hewawasam
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20170320833
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: July 20, 2017
    Publication date: November 9, 2017
    Inventors: MAKONEN BELEMA, Van N. Nguyen
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20170304239
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: September 3, 2015
    Publication date: October 26, 2017
    Applicant: ViiV Healthcare UK (No.5) Limited
    Inventors: Makonen BELEMA, John A. BENDER, Brett BENO, Robert G. GENTLES, Guo LI, Nicholas A. MEANWELL, Annapurna PENDRI, Zhong YANG, Shirong ZHU
  • Combinations comprising biphenyl derivatives for use in the treatment of HCV
    Patent number: 9775831
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: October 3, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark G. Saulnier, David B. Frennesson, Makonen Belema
  • Hepatitis C virus inhibitors
    Patent number: 9776981
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: October 3, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rico Lavoie, John A. Bender, Zhong Yang, Makonen Belema, Omar D. Lopez, Qi Chen, Gan Wang, Piyasena Hewawasam
  • Hepatitis C virus inhibitors
    Patent number: 9770439
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamunthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Ponugupati, Makonen Belema